A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma.
about
A new potential option for topical treatment of basal cell carcinoma?Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?The P2X7 Receptor.
P2860
A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@en
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@nl
type
label
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@en
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@nl
prefLabel
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@en
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@nl
P2093
P2860
P356
P1476
A phase I clinical trial demon ...... rapy for basal cell carcinoma.
@en
P2093
A Gidley Baird
J A Barden
S M Gilbert
P2860
P304
P356
10.1111/BJD.15364
P407
P577
2017-02-02T00:00:00Z